Docket #: S21-454
Cell-permeant inhibitors of viral cysteine proteases
The coronavirus main protease (Mpro), which is a trypsin-like protease with a catalytic cysteine residue, processes viral proteins in an early step of the coronavirus life cycle, and its activity is required for viral replication. Mpro represents a promising drug target for treatment of coronavirus diseases.
Stanford researchers have designed and developed a set of small-molecule protease inhibitors that inhibit the SARSCoV2 main protease with improved cell permeation or potency.
Stage of Development
In vivo: Mouse Studies
Applications
- Therapeutic for SARSCoV2 infections
Advantages
- Administration via oral, subcutaneous, intramuscular, or IV routes
- Increased stability compared to Pfizer small-molecule coronavirus protease inhibitor, PF-07321332
Related Links
Patents
- Published Application: WO2023114516
Similar Technologies
-
Small-Molecule Inhibitors of Gli Function S12-074Small-Molecule Inhibitors of Gli Function
-
FragFEATURE: Knowledge-based Fragment Binding Prediction using Unsupervised Machine Learning S14-069FragFEATURE: Knowledge-based Fragment Binding Prediction using Unsupervised Machine Learning
-
Synthetic Transcription Elongation Factors to Target Mutations in Cancer Genomes S22-104Synthetic Transcription Elongation Factors to Target Mutations in Cancer Genomes